Anna Pitsillidi, Laura Vona, Stefano Bettocchi, Sven Schiermeier, Günter Karl Noé
{"title":"PRP Therapy for Stress Urinary Incontinence and Pelvic Organ Prolapse: A New Frontier in Personalized Treatment?","authors":"Anna Pitsillidi, Laura Vona, Stefano Bettocchi, Sven Schiermeier, Günter Karl Noé","doi":"10.3390/jpm15060214","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Pelvic organ prolapse (POP) and stress incontinence (SUI) are very common medical conditions, affecting women's quality of life worldwide. Current surgical and conservative therapies often yield variable outcomes and carry risks of complications or recurrence. Platelet-rich plasma (PRP) has emerged as a promising regenerative approach in various medical disciplines. Its application in urogynecology remains relatively new and emerging. The objective of this study was to review and consolidate existing evidence regarding the application of PRP injections for treating POP and/or SUI. <b>Methods:</b> This scoping review was conducted in accordance with the Preferred Reporting Items for Scoping Reviews (PRISMA-ScR). The search strategy included MEDLINE (PubMed), Web of Science, and Scopus databases, covering articles published up to February 2025, with no restrictions on publication date. <b>Results:</b> We included in our review a total of 13 manuscripts and 320 patients at the end of the screening process. A total of ten SUI studies, comprising 273 patients, and three POP studies, involving 47 patients, satisfied all the review criteria. Both clinical entities reported high subjective improvement following PRP treatment. Moreover, PRP appeared to have no significant adverse effects. <b>Conclusions:</b> Our scoping review suggests that PRP may have potential benefits in the treatment of POP and SUI. Nevertheless, the current evidence on its application in this area remains limited. Therefore, well-designed, large-scale randomized controlled trials (RCTs) with extended follow-up periods are urgently needed, in the era of personalized medicine.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194431/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15060214","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pelvic organ prolapse (POP) and stress incontinence (SUI) are very common medical conditions, affecting women's quality of life worldwide. Current surgical and conservative therapies often yield variable outcomes and carry risks of complications or recurrence. Platelet-rich plasma (PRP) has emerged as a promising regenerative approach in various medical disciplines. Its application in urogynecology remains relatively new and emerging. The objective of this study was to review and consolidate existing evidence regarding the application of PRP injections for treating POP and/or SUI. Methods: This scoping review was conducted in accordance with the Preferred Reporting Items for Scoping Reviews (PRISMA-ScR). The search strategy included MEDLINE (PubMed), Web of Science, and Scopus databases, covering articles published up to February 2025, with no restrictions on publication date. Results: We included in our review a total of 13 manuscripts and 320 patients at the end of the screening process. A total of ten SUI studies, comprising 273 patients, and three POP studies, involving 47 patients, satisfied all the review criteria. Both clinical entities reported high subjective improvement following PRP treatment. Moreover, PRP appeared to have no significant adverse effects. Conclusions: Our scoping review suggests that PRP may have potential benefits in the treatment of POP and SUI. Nevertheless, the current evidence on its application in this area remains limited. Therefore, well-designed, large-scale randomized controlled trials (RCTs) with extended follow-up periods are urgently needed, in the era of personalized medicine.
背景:盆腔器官脱垂(POP)和压力性尿失禁(SUI)是非常常见的疾病,影响着全世界女性的生活质量。目前的手术和保守治疗往往产生不同的结果,并有并发症或复发的风险。富血小板血浆(PRP)已成为一种有前途的再生方法在各个医学学科。它在泌尿妇科的应用仍然相对较新。本研究的目的是回顾和巩固关于PRP注射治疗POP和/或SUI的应用的现有证据。方法:根据范围审查的首选报告项目(PRISMA-ScR)进行范围审查。搜索策略包括MEDLINE (PubMed)、Web of Science和Scopus数据库,涵盖2025年2月之前发表的文章,对发表日期没有限制。结果:在筛选过程结束时,我们共纳入了13篇论文和320名患者。共有10项SUI研究(273例患者)和3项POP研究(47例患者)满足所有评价标准。两个临床实体都报告了PRP治疗后的主观改善。此外,PRP似乎没有明显的不良反应。结论:我们的范围回顾表明PRP在治疗POP和SUI方面可能有潜在的益处。然而,目前关于其在这一领域应用的证据仍然有限。因此,在个性化医疗时代,迫切需要设计良好、随访期较长的大规模随机对照试验(RCTs)。
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.